Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination.

Autor:	Zachariah NN; Department of Breast Surgery, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Basu A; Clinical Science Division, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Gautam N; Clinical Science Division, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Ramamoorthi G; Clinical Science Division, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Kodumudi KN; Clinical Science Division, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Kumar NB; Clinical Science Division, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Loftus L; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Czerniecki BJ; Department of Breast Surgery, H. Lee Moffitt Cancer Center, Tampa, FL, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2021 Nov 24; Vol. 12, pp. 786286. Date of Electronic Publication: 2021 Nov 24 (Print Publication: 2021).
DOI:	10.3389/fimmu.2021.786286
Abstrakt:	Breast cancer (BC) prevention remains the ultimate cost-effective method to reduce the global burden of invasive breast cancer (IBC). To date, surgery and chemoprevention remain the main risk-reducing modalities for those with hereditary cancer syndromes, as well as high-risk non-hereditary breast lesions such as ADH, ALH, or LCIS. Ductal carcinoma in situ (DCIS) is a preinvasive malignant lesion of the breast that closely mirrors IBC and, if left untreated, develops into IBC in up to 50% of lesions. Certain high-risk patients with DCIS may have a 25% risk of developing recurrent DCIS or IBC, even after surgical resection. The development of breast cancer elicits a strong immune response, which brings to prominence the numerous advantages associated with immune-based cancer prevention over drug-based chemoprevention, supported by the success of dendritic cell vaccines targeting HER2-expressing BC. Vaccination against BC to prevent or interrupt the process of BC development remains elusive but is a viable option. Vaccination to intercept preinvasive or premalignant breast conditions may be possible by interrupting the expression pattern of various oncodrivers. Growth factors may also function as potential immune targets to prevent breast cancer progression. Furthermore, neoantigens also serve as effective targets for interception by virtue of strong immunogenicity. It is noteworthy that the immune response also needs to be strong enough to result in target lesion elimination to avoid immunoediting as it may occur in IBC arising from DCIS. Overall, if the issue of vaccine targets can be solved by interrupting premalignant lesions, there is a potential to prevent the development of IBC. Competing Interests: BC has a patent application filed for intellectual property on a human version of DC1. LL has stock in Johnson & Johnson, Pfizer, Eli Lilly, Gilead, and Amgen. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Zachariah, Basu, Gautam, Ramamoorthi, Kodumudi, Kumar, Loftus and Czerniecki.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu